ArticleBMC medical imaging2025
Comparative analysis of apparent diffusion coefficient (ADC) metrics for the differential diagnosis of breast mass lesions.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preoperative Breast MRI and Histopathology in Breast Cancer: Concordance, Challenges and Emerging Role of CEM and mpMRI.Diagnostics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer's diagnostic challenge is amplified by its heterogeneity. Diffusion-Weighted Imaging (DWI) offers promising avenues for precise tumor characterization through Apparent Diffusion Coefficient (ADC) metrics. PURPOSE: To investigate the diagnostic utility of advanced ADC metrics in distinguishing breast lesions using Magnetic Resonance Imaging (MRI).
methodsA retrospective cohort analysis of MRI data from 125 pathologically confirmed breast tumors was conducted. ADC values were independently measured by two physicians at the lesion sites and reference points (contralateral normal breast parenchyma, pectoralis major, and interventricular septum), from which advanced ADC metrics were calculated. Statistical analyses were applied to differentiate ADC metrics between malignant and benign groups. ROC curves assessed the diagnostic efficacy of individual ADC metrics. A binary logistic regression model incorporating ADC metrics and age was developed, with its diagnostic superiority evaluated through multidimensional comparisons.
resultsOf the 125 lesions, 77 were malignant and 48 benign. Significant differences in ADC metrics were found between malignant and benign tumors. Diagnostic analysis showed minimum ADC value (ADC_min) as the most effective single indicator, while the combined model, including age and average ADC value (ADC_avg), outperformed individual ADC metrics, demonstrating superior diagnostic accuracy (area under the curve (AUC) = 0.964). The combined model nomogram also showed improved clinical utility and a significant increase in diagnostic performance.
conclusionsAdvanced ADC metrics significantly enhance the diagnostic accuracy for differentiating between benign and malignant breast lesions. The development of a combined model further refines breast cancer diagnostics, supporting the advancement towards precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.